OTC Lice Treatment Recalled
Neogen Corporation is recalling 11 lots of LiceOut nonfoaming shampoo because of violations of Current Good Manufacturing Practice (CGMP) regulations, according to the December 4, 2024, US Food and Drug Administration (FDA) Enforcement Report. The report provides no further information about the CGMP violations.
The recall affects the following products:
- LiceOut nonfoaming shampoo, liquid lice treatment for human use, 1 fluid ounce (29.6 mL) per sachet (NDC 53427-124-01), from lot LO09530 (Exp. 9/5/25), and
- LiceOut nonfoaming shampoo, liquid lice treatment for human use, 128 fluid ounces (3785.4 mL) per jug (NDC 53247-124-02), from lots LO09530 (Exp. 11/3/24), LO13412 (Exp. 12/7/24), LO10263 (Exp. 1/26/25), LO11303 (Exp. 5/10/25), LO12153 (Exp. 8/3/25), LO12483 (Exp. 9/5/25), LO13183 (Exp. 11/14/25), LO106024 (Exp. 2/29/26), LO108624 (Exp. 3/26/26), and LO110224 (Exp. 4/11/26).
The affected LiceOut was sold to Bob Barker Company Inc, Fuquay-Varina, North Carolina, a company that sells supplies to prisons, jails, and other institutions, the FDA reported.
Neogen Corporation voluntarily initiated the recall on October 8, 2024. The FDA designated the recall Class II on November 27, 2024. The classification signals use of the product could cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.
LiceOut is an over-the-counter shampoo marketed for treating head, pubic, and body lice.
